Interesting paper concerning valuation of antibody licensing deals.
Says the majority of pre-clinical deals attracted below $10M, depending on a whole range of factors such as the pharma involved, milestone payments, number of candidates, and royalty arrangement.
It would be good to see Perseis arrange a deal prior to NNZ outcome to provide some kind of safety net should NNZ flop.
While the money may not be uber great, a bluechip Big Pharma signing up for our antibodies would provide validation of a pipeline product and put us on the radar.
http://www.venturevaluation.com/vv_web/files/BIO_2011_deal_making_antibody.pdf
perseis - value of licensing
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |